{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:54:05Z","timestamp":1780613645461,"version":"3.54.1"},"reference-count":30,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,9]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>Malaria is a major cause of death in low-income countries. Malaria relapses are caused by <jats:italic>Plasmodium vivax<\/jats:italic>\u2013induced latent liver stage hypnozoites, and relapses contribute significantly to the total disease burden. The goal of malaria elimination is threatened in countries where <jats:italic>P. vivax<\/jats:italic> is endemic and relapses remain a key aspect of concern. Targeting of the hypnozoites is crucial for radical cure and this is achieved by primaquine (PQ). In addition to its anti-hypnozoite effects, PQ also possesses gametocidal activity against all malaria causing <jats:italic>Plasmodium<\/jats:italic> species and is hence a useful tool to curtail malaria transmission. It is well known that host glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis after treatment with PQ. Multiple other host polymorphisms impact on PQ metabolism, potentially affecting drug efficacy. Being a prodrug, PQ requires host factors cytochrome P450 2D6 (CYP2D6), cytochrome P450 NADPH: oxidoreductase (CPR) and monoamine oxidase (MAO) for its metabolism and conversion to active form. The efficacy of PQ in the host is therefore dependent on genetic polymorphisms of these three host genes. The efficacy of PQ is important for clearing reservoirs of <jats:italic>P. vivax<\/jats:italic> infection. Here, we have analyzed the known spectrum of genetic polymorphisms for host genes that enable PQ metabolism. It is vital to delineate the polymorphisms that determine the ultimate efficacy of PQ for formulating better malaria elimination strategies in countries with severe malaria burden. Thus population-based studies of these gene variants will provide new insights into the role of host genetics on PQ treatment outcomes.<\/jats:p>","DOI":"10.4269\/ajtmh.21-1115","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T07:43:30Z","timestamp":1641800610000},"page":"764-767","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine"],"prefix":"10.4269","volume":"106","author":[{"given":"Minu","family":"Nain","sequence":"first","affiliation":[{"name":"National Institute of Malaria Research, New Delhi, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mradul","family":"Mohan","sequence":"additional","affiliation":[{"name":"National Institute of Malaria Research, New Delhi, India;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[{"name":"National Institute of Malaria Research, New Delhi, India;"},{"name":"Molecular Medicine, International Centre for Genetic Engineering and Biotechnology, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"J Infect","first-page":"231","article-title":"Epidemiology and clinical outcomes of severe Plasmodium vivax malaria in India","volume":"82:","year":"2021"},{"key":"b2","series-title":"Trends Parasitol","first-page":"560","article-title":"Plasmodium vivax in the era of the shrinking P. falciparum map","volume":"36:","year":"2020"},{"key":"b3","series-title":"PLoS Negl Trop Dis","first-page":"e0007525","article-title":"Correction: growing evidence of Plasmodium vivax across malaria-endemic Africa","volume":"13:","year":"2019"},{"key":"b4","author":"Hanboonkunupakarn","year":"2020"},{"key":"b5","series-title":"Malar J","first-page":"120","article-title":"Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa","volume":"17:","year":"2018"},{"key":"b6","series-title":"Clin Microbiol Rev","first-page":"e00011","article-title":"8-Aminoquinoline therapy for latent malaria","volume":"32:","year":"2019"},{"key":"b7","series-title":"BMJ Glob Health","first-page":"e004558","article-title":"Relapses of Plasmodium vivax malaria threaten disease elimination: time to deploy tafenoquine in India?","volume":"6:","year":"2021"},{"key":"b8","series-title":"PLoS Negl Trop Dis","first-page":"e0006230","article-title":"Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries","volume":"12:","year":"2018"},{"key":"b9","series-title":"Nat Commun","first-page":"3226","article-title":"Antimalarial activity of primaquine operates via a two-step biochemical relay","volume":"10:","year":"2019"},{"key":"b10","series-title":"Infect Genet Evol","first-page":"1228","article-title":"A large, systematic molecular-genetic study of G6PD in Indian populations identifies a new non-synonymous variant and supports recent positive selection","volume":"10:","year":"2010"},{"key":"b11","series-title":"J Pediatr Genet","first-page":"47","article-title":"Prevalence and genetic characterization of glucose-6-phosphate dehydrogenase deficiency in anemic subjects from Uttar Pradesh, India","volume":"8:","author":"Tripathi","year":"2019"},{"key":"b12","series-title":"Infect Genet Evol","first-page":"104597","article-title":"Prevalence and spectrum of mutations causing G6PD deficiency in Indian populations","volume":"86:","year":"2020"},{"key":"b13","series-title":"Ann Hum Biol","first-page":"55","article-title":"G6PD A- is the major cause of G6PD deficiency among the Siddis of Karnataka, India","volume":"47:","year":"2020"},{"key":"b14","series-title":"Indian J Hematol Blood Transfus","first-page":"349","article-title":"Molecular characterization of G6PD deficiency: report of three novel G6PD variants","volume":"36:","year":"2020"},{"key":"b15","series-title":"J Trop Med","first-page":"1","article-title":"Molecular characterization of glucose-6-phosphate dehydrogenase: do single nucleotide polymorphisms affect hematological parameters in HIV-positive patients?","volume":"2020:","year":"2020"},{"key":"b16","series-title":"N Engl J Med","first-page":"1381","article-title":"Primaquine failure and cytochrome P-450 2D6 in plasmodium vivax Malaria","volume":"369:","year":"2013"},{"key":"b17","series-title":"Clin Pharmacol Ther","first-page":"688","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102:","year":"2017"},{"key":"b18","series-title":"JAMA Netw Open","first-page":"e181449","article-title":"Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of Primaquine treatment for latent Plasmodium vivax malaria","volume":"1:","year":"2018"},{"key":"b19","series-title":"Clin Pharmacol Ther","first-page":"376","article-title":"Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95:","year":"2014"},{"key":"b20","series-title":"Am J Trop Med Hyg","first-page":"756","article-title":"Prevalence of CYP2D6 genotypes and predicted phenotypes in a cohort of Cambodians at high risk for infections with Plasmodium vivax.","volume":"103:","year":"2020"},{"key":"b21","series-title":"Front Pharmacol","first-page":"103","article-title":"Pharmacogenomics of human P450 oxidoreductase","volume":"5:","year":"2014"},{"key":"b22","series-title":"J Ovarian Res","first-page":"16","article-title":"Cytochrome P450 oxidoreductase deficiency caused by R457H mutation in POR gene in Chinese: case report and literature review","volume":"10:","year":"2017"},{"key":"b23","series-title":"Exp Toxicol Pathol","first-page":"299","article-title":"Metabolism of primaquine by liver homogenate fractions","volume":"51:","year":"1999"},{"key":"b24","series-title":"Malar J","first-page":"259","article-title":"CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine","volume":"11:","year":"2012"},{"key":"b25","series-title":"Parasitol Res","first-page":"1011","article-title":"Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers","volume":"118:","year":"2019"},{"key":"b26","series-title":"Proc Natl Acad Sci USA","first-page":"862","article-title":"Evidence for positive selection and population structure at the human MAO-A gene","volume":"99:","year":"2002"},{"key":"b27","series-title":"J Mol Evol","first-page":"157","article-title":"The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa","volume":"52:","year":"2001"},{"key":"b28","series-title":"Pharmacol Toxicol","first-page":"133","article-title":"Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase","volume":"515:","year":"2019"},{"key":"b29","series-title":"Am J Trop Med Hyg","first-page":"1094","article-title":"Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis","volume":"103:","year":"2020"},{"key":"b30","series-title":"Pharmacogenet Genomics","first-page":"677","article-title":"Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in\u00a0vitro","volume":"20:","year":"2010"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/106\/3\/article-p764.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/106\/3\/article-p764.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/106\/3\/article-p764.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:48:58Z","timestamp":1760964538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/106\/3\/article-p764.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":30,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.21-1115","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}